Hypothesis

Increasing mitochondrial DNA (mtDNA) copy number in post‑mitotic tissues restores a youthful nuclear epigenetic landscape by normalizing retrograde ROS‑NAD+ signaling, thereby delaying age‑related decline independent of nuclear genome editing.

Mechanistic Rationale

mtDNA mutations accumulate with age and trigger focal respiratory defects that elevate local ROS [1][2]. This ROS surge consumes NAD+ through PARP activation, lowering the NAD+/NADH ratio and dampening SIRT1 activity [3]. SIRT1 normally deacetylates histones and transcription factors such as NF‑κB and PGC‑1α, maintaining a chromatin state conducive to mitochondrial biogenesis and stress resistance [4]. When SIRT1 wanes, histone acetylation rises at promoters of inflammatory genes, while PGC‑1α activity falls, creating a vicious cycle of mito‑nuclear mismatch.

Boosting mtDNA copy number—via TFAM overexpression or enhanced mito‑biogenesis—dilutes the proportion of mutated genomes, reduces ROS per mitochondrion, and raises total NAD+ production. The improved NAD+/NADH ratio reactivates SIRT1, which then re‑establishes youthful acetylation patterns on nuclear chromatin. In this view, mtDNA acts as a metabolic rheostat that sets the epigenetic tempo of the nucleus, rather than merely a passive damage target.

Predictions & Experimental Design

1. Rescue of heteroplasmy impact: In mtDNA‑mutator mice (PolG^D257A/D257A), AAV9‑mediated TFAM delivery to skeletal muscle will increase mtDNA copy number by ~2‑fold and lower heteroplasmy levels at COX‑deficient fibers from >70% to <30% after 8 weeks [5].
2. Epigenetic normalization: Muscle nuclei from treated mice will show reduced H3K27ac at NF‑κB target loci and increased H3K9me3 at senescence‑associated secretory phenotype (SASP) promoters, matching the profile of young wild‑type tissue [6].
3. Functional outcome: Treated mutator mice will exhibit improved grip strength (+25%), enhanced treadmill endurance (+30%), and extended median lifespan (~15% increase) compared with untreated mutator controls.

Experimental groups (n=15 per group): wild‑type + AAV‑GFP, mutator + AAV‑GFP, mutator + AAV‑TFAM. Endpoints measured at 4, 8, and 12 months include mtDNA copy number (qPCR), heteroplasmy (digital droplet PCR), NAD+/NADH ratio (enzymatic assay), SIRT1 activity (fluorometric deacetylase assay), chromatin immunoprecipitation sequencing for H3K27ac/H3K9me3, and physiological assays.

Potential Outcomes & Falsifiability

If TFAM‑driven mtDNA copy elevation fails to alter heteroplasmy, NAD+/NADH ratios, or nuclear acetylation patterns, and no functional improvement is observed, the hypothesis that mtDNA copy number sets the epigenetic pace of aging would be falsified. Conversely, a concordant shift in metabolite signaling, chromatin state, and tissue‑level performance would support the model, suggesting that therapeutic strategies targeting mtDNA abundance could complement—or in certain contexts supersede—direct nuclear genome edits for age‑related decline.